Advertisement

Topics

Daiichi-Sankyo Company Profile

23:37 EST 18th November 2017 | BioPortfolio


News Articles [177 Associated News Articles listed on BioPortfolio]

Daiichi Sankyo, Boston Pharmaceuticals sign deal for selective RET inhibitor for solid tumors

Daiichi Sankyo and Boston Pharmaceuticals have entered into a worldwide licensing agreement for Daiichi Sankyo's novel RET inhibitor, DS-5010.

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s DS-8201 for HER2-Positive Metastatic Breast Cancer

Tokyo, Japan, Basking Ridge, NJ, and Munich, Germany – (August 29, 2017) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration (F...

MD Anderson, Daiichi Sankyo Partner to Develop AML Treatments

The University of Texas MD Anderson Cancer Center and Daiichi Sankyo said today they plan to develop novel therapies for acute myeloid leukemia (AML) through a multi-year collaboration whose value was...

Daiichi Sankyo settles US products liability litigation

Japanese pharma major Daiichi Sankyo (TYO: 4568) and its US subsidiary have agreed to enter into a…

Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center collaborate

Daiichi Sankyo, Max Planck Innovation and the Lead Discovery Center have signed an agreement providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the tre...

Daiichi Sankyo & Glycotope Enter Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing

TOKYO and BASKING RIDGE, N.J., and BERLIN, Oct. 30, 2017 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have signed an optio...

Daiichi Sankyo links with German academia for cancer research

Japanese pharma major Daiichi Sankyo has signed an agreement with Germany’s Max Planck Innovation…

Daiichi Sankyo pulls out of Charleston Labs deal; reports on mirogabalin

Japanese drug major Daiichi Sankyo, and its US subsidiary, have elected to terminate its 2014 development…

Drugs and Medications [11 Associated Drugs and Medications listed on BioPortfolio]

Benicar [Daiichi Sankyo, Inc]

These highlights do not include all the information needed to use Benicar safely and effectively. See full prescribing information for Benicar. Benicar (olmesartan medoxomil) tablets Initial U.S. Appr...

Evoxac capsules(cevimeline hydrochloride) [Daiichi Sankyo Pharma Development]

EVOXAC Capsules(cevimeline hydrochloride)

Azor [Daiichi Sankyo, Inc.]

These highlights do not include all the information needed to use AZOR safely and effectively. See full prescribing information for AZOR. AZOR (amlodipine and olmesartan medoxomil) tablets, for oral u...

Welchol [Daiichi Sankyo, inc.]

These highlights do not include all the information needed to use Welchol safely and effectively. See full prescribing information for Welchol. Welchol (colesevelam hydrochloride) Tablet, Film Coated,...

Quixin [Vistakon Pharmaceuticals LLC]

QUIXIN (levofloxacin ophthalmic solution) 0.5%

PubMed Articles [18 Associated PubMed Articles listed on BioPortfolio]

New Navigation Surgery for Resection of Lymphatic Malformations Using Indocyanine Green Fluorescence Imaging.

BACKGROUND We used indocyanine green (ICG) fluorescence imaging to completely resect lymphatic malformations (LMs). This is the first report of navigation surgery utilizing ICG fluorescence imaging fo...

Lessons Learned in Protection of the Public for the Accident at the Fukushima Daiichi Nuclear Power Plant.

What insights can the accident at the Fukushima Daiichi nuclear power plant provide in the reality of decision making on actions to protect the public during a severe reactor and spent fuel pool emerg...

Birth Outcomes after the Fukushima Daiichi Nuclear Power Plant Disaster: A Long-Term Retrospective Study.

Changes in population birth outcomes, including increases in low birthweight or preterm births, have been documented after natural and manmade disasters. However, information is limited following the ...

Isotopic signature and nano-texture of cesium-rich micro-particles: Release of uranium and fission products from the Fukushima Daiichi Nuclear Power Plant.

Highly radioactive cesium-rich microparticles (CsMPs) released from the Fukushima Daiichi Nuclear Power Plant (FDNPP) provide nano-scale chemical fingerprints of the 2011 tragedy. U, Cs, Ba, Rb, K, an...

Spatial pattern of atmospherically deposited radiocesium on the forest floor in the early phase of the Fukushima Daiichi Nuclear Power Plant accident.

Spatial patterns of atmospherically deposited radiocesium on the forest floor and the temporal evolution were measured in two Japanese cedar stands and a secondary mixed broad-leaved forest in the ear...

Clinical Trials [12 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Olmesartan Medoxomil Tablets 40 mg and Benicar® 40 mg Tablets of Daiichi Sankyo Inc., USA. Dosing periods of studies were ...

Comparative Study of Loxoprofen Sodium Transdermal Patch and Loxonin® Tablets for the Treatment of Acute Trauma

This study evaluates the non-inferiority of the new transdermal patch dosage form containing loxoprofen sodium (100 mg - Daiichi-Sankyo) in comparison with oral Loxonin® (60 mg tablet - D...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablet Under Fasting Conditions

Subjects to compare the single dose bioavailability of Torrent's Olmesartan Medoxomil Tablets 40 mg and Benicar 40 mg Tablets of Daichi Sankyo Inc. USA. Dosing periods of studies were sepa...

Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)

In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the NVAF indication, Daiichi-Sankyo Hong Kong proposed this non-interventional study (NIS)...

Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)

In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the NVAF indication, Daiichi-Sankyo Thailand proposed this non-interventional study (NIS) ...

Companies [28 Associated Companies listed on BioPortfolio]

DAIICHI SANKYO EUROPE GmbH and SHARE

DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese e...

Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. ...

Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the joint share transfer of two leading century-old Japanese pharmaceutical companies, is continuously generating innovative drugs that e...

ArQule, Inc. and Daiichi Sankyo Company, Limited

On December 19, 2008, ArQule and Daiichi Sankyo, Co., Ltd. signed a license, co-development and co-commercialization agreement to co-develop tivantinib in the U.S., Europe, South ...

Daiichi-Sankyo

More Information about "Daiichi-Sankyo" on BioPortfolio

We have published hundreds of Daiichi-Sankyo news stories on BioPortfolio along with dozens of Daiichi-Sankyo Clinical Trials and PubMed Articles about Daiichi-Sankyo for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Daiichi-Sankyo Companies in our database. You can also find out about relevant Daiichi-Sankyo Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record